RA Capital led the companys $336 million Series C ahead of the companys August IPO, though the firm hadnt participated in the companys earlier funding rounds. The Legal 500; Europe, Middle East & Africa . Current biopharma portfolio companies: Hyperion Therapeutics, OpGen, City (cities) where offices are located: Menlo Park, CA; Westport, CT; New York; Gurgaon, India; Herzliya Pituach, Israel, Fund size and status: $4.2 billion under management across nine funds, Current fund: $675 million Canaan Partners X, announced Oct. 16, Current biopharma portfolio companies: Aldea Pharmaceuticals, Arvinas, Axial Exchange, Chimerix, Chrono Therapeutics, CytomX, Dermira, Durata Therapeutics, Envisia Therapeutics, LQ3 Pharma, Marinus Pharmaceuticals, Novira Therapeutics, Sample6, Semnur Pharmaceuticals, Spinifex Pharmaceuticals, Theraclone Sciences, Tobira Therapeutics, VaxInnate, City (cities) where offices are located: New York; San Francisco; Mumbai; Shanghai; Herzliya, Israel, Fund size and status: Approximately $12 billion under management in five public funds, as well as private equity funds in North America/Europe, Asia, and Israel; and a Royalty Opportunities Fund launched 2011 to invest in healthcare royalty streams, Current fund: $325 million OrbiMed Asia Partners II, closed September; $735 million OrbiMed Private Investments V, closed October 2013, Current biopharma portfolio companies: Acceleron Pharma, Adaptimmune, Aerocrine, Adimab, Aerpio, Affimed, Alector, Amarin, Ambit Biosciences, Anthera, arGEN-X, ARMO BioSciences, Arsanis Biosciences, Arteaus, Audentes Therapeutics, Avitide, Bharat Serums and Vaccines, Biodel, BioLineRx, Cardioxyl, cCAM Biotherapeutics, Cerenis Therapeutics, Cleave Biosciences, Clementia, Dimension Therapeutics, Durata Therapeutics, Eddingpharm, GC-Rise Pharmaceutical, Good Start Genetics, Igenica, Intercept Pharmaceuticals, Invitae, Iroko Pharmaceuticals, Loxo Oncology, Mirati Therapeutics, Otic Pharma, Otonomy, OxOnc Development, PharmAbcine, Pieris, Principia Biopharma, ProNAi, RDD Pharma, RedHill Biopharma, Relypsa, Response BioMedical, Roka BioScience, Sage Therapeutics, Selecta Biosciences, Shasun, singulex, Symbionics Therapeutics, Waterstone Pharmaceuticals, #2. WebFive out of the ten businesses selected to present at the 2021 event went on to raise $50m - $150m each within 12 months of the event and one raising a $23m Series A (others planning to raise in the next 6 months). Exclusive analysis of biotech, pharma, and the life sciences, https://reports.statnews.com/products/2021-ranking-biotechs-top-venture-capital-firms?utm_source=statnews.com&utm_medium=referral&utm_campaign=stat_reports_articlewidget2.0&utm_content=0621sub-header1, Reporting from the frontiers of health and medicine, You've been selected! Insider analyzed corporate filings to identify the venture-capital firms that shaped these biotechs and are positioned to build on their success in 2022. Versant had a busy 2021: It was involved in five IPOs. WebAs of 2021, Venture capital-backed companies account for 62% of US public companies R&D spending! Blackstone, one of the largest private venture capital firms, founded Blackstone Life Sciences in 2018 after acquiring Clarus Ventures, an equity firm with $2.6 billion in assets. Asia Pacific ; The rise in transaction volume may be attributed to the increase in transaction sizes as the top firms receive extensive working capital. The firm seeks to accelerate companies in the software, media and technology sectors in Texas. Partner Ernst Theodor Sack, Vaughn Blake, Robert Macinnis, PH.D. Founded in 2005, S3 Ventures is a venture capital firm based in Austin, Texas. Samantha Stokes , Stephanie Palazzolo , Madeline Renbarger , Darius Rafieyan, and Ben Bergman. WebMarket-leading rankings and editorial commentary - see the top law firms & lawyers for Private equity: venture/growth capital in France. The Legal 500 > United States > United States > M&A/corporate and commercial > Venture capital and emerging companies. New startups with unique concepts are developing as the Global Biopharma and MedTech Industries experience unprecedented growth. Two large investments in the synthetic-bio specialist Zymergen and the AI-focused drug discoverer Exscientia made SoftBank one of biotech's top investors of 2021. The company focuses its investments on both early and late-stage life sciences enterprises. The stampede is back on among venture capital firms to raise new money and close more funds, after years of standing pat following the recession and years of sluggish recovery. Added to this, a new administration in the United States and its policy proposals, taxes, immigration, trade policy, and other issues that directly affect both VC investors and companies will all be on the table next year, PitchBook said in its 2021 U.S. venture capital outlook report. Founded in 2006, Breyer Capital is a venture capital firm headquartered in Menlo Park, California. When Third Rock Ventures was established in 2007, the prospect of turning scientific advancements into ground-breaking medications set public imaginations on fire. 9 See announcement on the firms blog, http://indexventures.com/news-room/blog/our-new-fund-for-building-iconic-businesses The teams diversity and integration offer in-depth expertise that produces tangible outcomes for its businesses and investors. New Leaf Venture Partners (NLVP) invested in Biopharmaceuticals during its growth and venture phases. The firm specializes in investing in the early-stage firm. See: http://www.sec.gov/Archives/edgar/data/1609495/000160949214000002/xslFormDX01/primary_doc.xml MPM BioVentures was approaching the end of fundraising, according to an unnamed market source, Reuters PE Hub reported on Sept. 18. The two main areas for venture capitalist (VC) investment - technology and healthcare - have grown during the COVID-19 pandemic and investors have ample dry The ecosystem of Biotech ventures peaked in 2021. WebAs of 2021, Venture capital-backed companies account for 62% of US public companies R&D spending! VC firms only invest in companies that have long-term growth potential of at least 10X their investment, and that already have considerable traction (very fast revenue Fund size and status: More than $3 billion in committed capital across nine funds. Boston-based RA Capital Management and New York-based OrbiMed ranked first and second, respectively, on the two lists compiled using Crunchbase data. See: http://www.sec.gov/Archives/edgar/data/1612343/000161234314000001/xslFormDX01/primary_doc.xml The company is steadily growing its life science footprint, emphasizing infrastructure, financial instruments, and real estate. Biotech is just one piece of its portfolio Mubadala also invests in aerospace, renewable energy, real estate, and several other industries. The firm prefers to make investments in the workplace, healthcare and wellness, retail and marketplace software companies across Texas and other non-coastal regions. Bill Wood Ventures is a venture capital firm based in Austin, Texas. These startups and companies are taking a variety of approaches to innovating the Venture Capital industry, but are all exceptional companies Fierce Life Sciences Events. Flagship, based in Cambridge, Massachusetts, is more of a venture-creation firm than a traditional VC it often creates the companies it invests in. Flagship Pioneering offers a distinctive business strategy that conceives, develops, finances, and expands first-in-category ventures to revolutionize sustainability and human health. Founding Partners Carl Soderstrom and Clay Heighten, MD. Additionally, Bain Capital Crypto closed a $500 million fund in March 2022, and the firm announced a $2.4 billion Tech Opportunities fund earlier this month. It's structured as five teams with different investment focuses, investing in both tiny biotech startups and established biopharma companies. Latest biotech merger sees aimless Adamis snapped up by DMK - FierceBiotech 4h ago 14On June 27, KPCB submitted Form D filings with the U.S. Securities and Exchange Commission disclosing plans to raise an early-stage growth fund of $450 million, known as KPCB XVI, as well as a later-stage fund of $750 million known as KPCB Digital Growth. Versant, based in San Francisco, has $4.1 billion in assets under management and makes a handful of investments in new companies each year, typically investing $20 million to $30 million, a spokesperson said. Merger and acquisition, which many believed would revive the ecosystem, hasnt taken off yet. 1640 Highland Falls Dr, Ste #302, The firm seeks investments in seed-stage, early-stage and later-stage companies. Business Products and Services (B2B), Healthcare Technology Systems, Information Technology, Founder & Managing Partner Leonard Lenny Saizan Jr. , which conducts research and development of pharmaceuticals related to COVID-19. 6. Polaris describes the seventh fund as a partnership investing in technology and healthcare. See: http://myemail.constantcontact.com/Announcing-Fund-VII.html?soid=1106633098844&aid=84wvr4fxTTs The firm seeks to make minority investments in seed, early-stage, and later-stage companies. It features some jaw Third-ranked Flagship Pioneering, for instance, was driven by just two IPOs in 2021. It's a great way to keep an eye on up-and-coming companies with In 2021, the health and biotech industry was second to only Fintech by VC investment raised. Also includes one tools & services company, Rapid Micro Biosystems, which focuses on detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. PitchBook has published its 2021 U.S. Venture Capital Outlook report. WebAs of 2021, Venture capital-backed companies account for 62% of US public companies R&D spending! In addition to an increased focus on algorithm engineering and digital health technologies, Third Rock Ventures has a history of investing in the Biotechnology sector. WebThe 45 most important VCs in Texas, according to other VCs. That seventh fund closed $50 million higher than the $400 million offering amount that the firm stated back on June 17, when it disclosed its plan to raise the fund in a Form D filing with the U.S. Securities and Exchange Commission. Business Products and Services (B2B), Consumer Products and Services (B2C), Financial Services, Information Technology, Materials and Resources. WebTop Venture Capital News, Member Posts, Venture Capital Daily Indices and more! Application Software, Beverages, Business/Productivity Software, Communication Software, Database Software, Education and Training Services (B2B), Educational and Training Services (B2C), Food Products, Healthcare Technology Systems, Other Media, Other Software, Pharmaceuticals and Biotechnology, Security Services (B2B), Social Content, Social/Platform Software, Water Utilities. Largest investment: 18.2 million shares of Adagio Therapeutics worth $46.9 million at the time of its IPO, Total holding value of 2021 IPOs: $468.7 million. At the end of September, Flagship had $17 billion in assets under management. The investments we included were those disclosed in company S-1 filings, and the value of the holdings was based on the companies' initial pricing at the time of their IPOs. The firm primarily prefers to invest in the information technology sectors. CEO: Andrew Sheiner. Khosla Ventures bears the interests of Vinods passion for mentoring founders and entrepreneurs. Founded in 2005, Mercury Fund is a venture capital firm based in Houston, Texas. Founded in 2019, Springdale Ventures is a venture capital firm based in Austin, Texas. Fierce Pharma. Largest investment: 9.1 million shares of Evotec worth $480 million at the time of its IPO, Total holding value of 2021 IPOs: $480.4 million. 11 On Nov. 14, the firm submitted a Form D filing stating that partners were raising funds toward a ninth fund, to be named Bessemer Venture Partners IX Institutional. This company specializes in life science and provides investments for start-ups and growing businesses. Founded in 2012, Social Starts is a set of early-stage venture funds that uses analytics to uncover and invest in the strongest companies in the strongest investment segments.